文献速递功能神经外科

丘脑深部脑刺激治疗痉挛性发声障碍:I期前瞻性随机双盲交叉试验

Thalamic Deep Brain Stimulation for Spasmodic Dysphonia: A Phase I Prospective Randomized Double-Blind Crossover Trial.
PubMed 文献 · Neurosurgery · 2021-01-01

这项I期前瞻性随机双盲交叉试验纳入6例内收型痉挛性发声障碍患者,评估左侧丘脑腹中间核(Vim)深部脑刺激(DBS)的安全性及疗效。 blinded阶段DBS「开」与「关」相比,生活质量和嗓音质量均呈改善趋势(P=.07和P=.06),但样本量小未达统计学显著。1年开放标签随访显示情绪和生活质量改善,认知无差异。

要点

  • Vim丘脑DBS在痉挛性发声障碍患者中可安全实施,无并发症。
  • 双盲阶段DBS「开」时生活质量和嗓音质量呈改善趋势但未达显著。
  • 小脑环路而非苍白球环路可能对声带运动控制至关重要。

核心结论

  • I期随机对照试验证实DBS可安全用于痉挛性发声障碍患者。
  • 双盲DBS使生活质量和客观嗓音质量呈强烈改善趋势,但样本量小未达统计学显著。
  • 小脑环路而非苍白球环路似乎对声带运动控制至关重要。

研究设计与样本

  • I期前瞻性随机双盲交叉试验,纳入6例内收型痉挛性发声障碍患者。
  • 患者接受左侧Vim丘脑DBS,随机分配至3个月双盲DBS「开」或「关」,随后交叉。
  • 主要结局为双盲阶段的生活质量和嗓音质量,患者继续开放标签DBS「开」。
  • 次要结局为基线与1年时认知、情绪和生活质量的比较。
  • 试验注册于ClinicalTrials.gov(NCT02558634)。

主要发现

  • 无并发症发生。
  • 双盲DBS「开」与「关」相比,每例患者均报告生活质量改善(P=.07)和嗓音质量改善(P=.06)。
  • 样本量小,趋势未达统计学显著。
  • 次要结局显示认知无差异,1年时情绪和生活质量改善。

临床怎么用

  • Vim丘脑DBS可作为痉挛性发声障碍的一种安全试验性治疗选择。
  • 当前标准治疗仍为重复肉毒毒素注射以削弱内收肌。
  • DBS的疗效需更大样本试验进一步验证。

局限性

  • 样本量小(6例),主要结局未达统计学显著。
  • 为I期试验,主要目的是评估安全性。
  • 双盲阶段仅3个月,长期疗效需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adductor spasmodic dysphonia (SD) is a dystonia of the vocal folds causing difficulty with speech. The current standard of care is repeated botulinum toxin injections to weaken the adductor muscles. We sought to ameliorate the underlying neurological cause of SD with a novel therapy-deep brain stimulation (DBS). OBJECTIVE: To assess the safety of DBS in SD through phase I trial, and to quantify the magnitude of any benefit. METHODS: Six patients had left ventral intermediate nucleus (Vim) thalamic DBS and were randomized to 3 mo blinded-DBS "on" or "off" followed by a crossover. Primary outcomes were quality of life and quality of voice during the blinded phase. Patients continued with open-DBS "on." Secondary outcomes were comparisons of pre- and 1-yr cognitive, mood, and quality of life. This trial was registered with ClinicalTrials.gov (NCT02558634). RESULTS: There were no complications. Every patient reported an improvement in quality of life (P = .07) and had an improvement in quality of their voice (P = .06) when their blinded DBS was "on" versus "off." The trend did not reach statistical significance with the small sample size. Secondary outcomes showed no difference in cognition, an improvement in mood, and quality of life at 1 yr. CONCLUSION: This phase I randomized controlled trial confirmed that DBS can be performed safely in patients with SD. Blinded DBS produced a strong trend toward improved quality of life and objective quality of voice despite the small sample size. The cerebellar circuit, not the pallidal circuit, appears to be crucial for motor control of the vocal folds.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Honey CR, Krüger MT, Almeida T, et al. Thalamic Deep Brain Stimulation for Spasmodic Dysphonia: A Phase I Prospective Randomized Double-Blind Crossover Trial. Neurosurgery. 2021. PMID: 33862624. doi:10.1093/neuros/nyab095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。